Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study-Reference-Cited by-同舟云学术

Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study

Published:2022-03-15 Issue:6 Volume:29 Page:533-540
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Uemura Hirotsugu¹^ORCID,Arai Gaku²,Uemura Hiroji³,Suzuki Hiroyoshi⁴,Aoyama Junya⁵^ORCID,Hatayama Tomoyoshi⁵^ORCID,Ito Miku⁵^ORCID,Lefresne Florence⁶,McCarthy Sharon⁷,Mundle Suneel⁷,He Jin⁸,Chi Kim N⁹

Affiliation:

1. Department of Urology Kindai University Hospital Osakasayama Osaka Japan

2. Department of Urology Dokkyo Medical University Saitama Medical Center Koshigaya Saitama Japan

3. Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan

4. Department of Urology Toho University Sakura Medical Center Sakura Chiba Japan

5. Janssen Pharmaceutical K.K. Tokyo Japan

6. Janssen Research and Development Los Angeles California USA

7. Janssen Research and Development US Raritan New Jersey USA

8. Janssen Asia Pacific, Medical Affairs Singapore

9. BC Cancer and Vancouver Prostate Centre Vancouver British Columbia Canada

Funder

Janssen Research and Development